John Montalbano Joins AbCellera’s Board of DirectorsNovember 18, 2020
VANCOUVER, British Columbia–(BUSINESS WIRE)–AbCellera, a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease, today announced the appointment of John Montalbano to its Board of Directors. Mr. Montalbano will serve as the Chair of the Audit Committee of the Board of Directors.
“John is both an internationally respected business leader and a pillar of the Vancouver community. He brings deep financial expertise and first-hand operational experience in running large and complex organizations that succeed on the world stage,” said Carl Hansen, Ph.D., CEO of AbCellera. “We are delighted to have him join and warmly welcome him onto our board.”
Mr. Montalbano is Principal of Tower Beach Capital Ltd. and serves on the boards of the Canada Pension Plan Investment Board, Aritzia Inc., and the Asia Pacific Foundation of Canada. His previous appointments include the former Vice Chair of RBC Wealth Management and CEO of RBC Global Asset Management (RBC GAM). When Mr. Montalbano retired as CEO of RBC GAM in 2015, it was among the largest 50 asset managers worldwide with $370 billion under management and offices in Canada, the United States, the United Kingdom, and Hong Kong.
“AbCellera is doing meaningful work that has a global impact,” said John Montalbano. “I look forward to working closely with the board and management during this exciting time of significant growth for the company. (Read more…)”
Mr. Montalbano holds a Chartered Financial Analyst designation and a Bachelor of Commerce, with Honours, from the University of British Columbia (UBC). He is a Leslie Wong Fellow of the UBC Portfolio Management Foundation and holds an Honorary Doctor of Letters from Emily Carr University of Art and Design.
About AbCellera Biologics Inc.
AbCellera is a privately held technology company with an antibody discovery platform that searches, decodes, and analyzes natural immune systems to find antibodies that can be used to prevent and treat disease. AbCellera’s technology, which combines high-throughput microfluidics, hyper-scale data science, machine learning, bioinformatics, and genomics, identifies new drug candidates and aims to reduce the time it takes to bring treatments to the clinic. AbCellera’s partners include leading biotechnology companies, global health organizations, and many of the top 10 biopharmaceutical companies. For more information, visit www.abcellera.com.